PubMed

Using cost-effectiveness to target cholesterol reduction.

Beaird J.

Ann Intern Med. 2001 Aug 21;135(4):299-300. No abstract available. PMID: 11511147 [PubMed - indexed for MEDLINE]Related articlesFree article

Using cost-effectiveness analysis to target cholesterol reduction.

Garber AM.

Ann Intern Med. 2000 May 16;132(10):833-5. No abstract available. PMID: 10819708 [PubMed - indexed for MEDLINE]Related articlesFree article

Economic aspects of hypercholesterolemia treatment with HMG-CoA reductase inhibitors: a review of recent developments.

MacNeil P.

Can J Cardiol. 1998 Apr;14 Suppl A:14A-16A. Review.PMID: 9594928 [PubMed - indexed for MEDLINE]Related articles

Cost effectiveness of treatment to National Cholesterol Education Panel (NCEP) targets with HMG-CoA reductase inhibitors. Trial design.

Black D, Davidson M, Koren M, Bakker-Arkema R, Tresh P, McLain R, Smith D, Hunninghake D.

Pharmacoeconomics. 1997 Aug;12(2 Pt 2):278-85.PMID: 10170452 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.

Plans-Rubió P.

Am J Cardiovasc Drugs. 2006;6(3):177-88.PMID: 16780391 [PubMed - indexed for MEDLINE]Related articles

Development and validation of a model to project the long-term benefit and cost of alternative lipid-lowering strategies in patients with hypercholesterolaemia.

Cook JR, Yin D, Alemao E, Drummond M.

Pharmacoeconomics. 2004;22 Suppl 3:37-48.PMID: 15669152 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness analyses.

Clark CM.

Ann Intern Med. 2001 Sep 4;135(5):382-3. No abstract available. PMID: 11529708 [PubMed - indexed for MEDLINE]Related articlesFree article

[When cholesterol lowering drugs should not be too expensive. Statins are especially effective in secondary prevention]

Thomas HP, Kassner U, Steinhagen-Thiessen E.

MMW Fortschr Med. 2000 Jul 27;142(30):33-4. German. No abstract available. PMID: 10955017 [PubMed - indexed for MEDLINE]Related articles

By the way, doctor. I have high cholesterol, and have been taking Mevacor (lovastatin) for two years. Recently, I was switched to Pravachol (pravastatin) because my insurance company would no longer pay for Mevacor. Is it as good?

Nicholson CR.

Harv Womens Health Watch. 1999 Jun;6(10):8. No abstract available. PMID: 10233830 [PubMed - indexed for MEDLINE]Related articles

Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.

Malhotra HS, Goa KL.

Drugs. 2001;61(12):1835-81. Review.PMID: 11693468 [PubMed - indexed for MEDLINE]Related articles

Rosuvastatin is cost-effective compared with atorvastatin in reaching cholesterol goals.

Hirsch M, O'donnell J, Olsson A.

Int J Cardiol. 2005 Oct 10;104(3):251-6.PMID: 16186052 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goal: application to Germany, Spain and Norway.

Cook JR, Yin D, Alemao E, Davies G, Krobot KJ, Veltri E, Lipka L, Badia X.

Pharmacoeconomics. 2004;22 Suppl 3:49-61.PMID: 15669153 [PubMed - indexed for MEDLINE]Related articles

Economic evaluation of a compliance-enhancing intervention in patients with hypercholesterolemia: design and baseline results of the Open Label Primary Care Study: Rosuvastatin Based Compliance Initiatives To Achievements of LDL Goals (ORBITAL) study.

Willich SN, Müller-Nordhorn J, Sonntag F, Völler H, Meyer-Sabellek W, Wegscheider K, Windler E, Katus H.

Am Heart J. 2004 Dec;148(6):1060-7.PMID: 15632894 [PubMed - indexed for MEDLINE]Related articles

The new National Cholesterol Education Program guidelines: clinical challenges for more widespread therapy of lipids to treat and prevent coronary heart disease.

Eidelman RS, Lamas GA, Hennekens CH.

Arch Intern Med. 2002 Oct 14;162(18):2033-6. No abstract available. PMID: 12374510 [PubMed - indexed for MEDLINE]Related articles

Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a Primary Care setting.

Usher-Smith JA, Ramsbottom T, Pearmain H, Kirby M.

Int J Clin Pract. 2007 Jan;61(1):15-23.PMID: 17229176 [PubMed - indexed for MEDLINE]Related articles

Integrating economic analysis into clinical trials.

Imai K, Zhang P.

Lancet. 2005 May 21-27;365(9473):1749-50. No abstract available. PMID: 15910936 [PubMed - indexed for MEDLINE]Related articles

Lipid-modifying therapy and attainment of cholesterol goals in Hungary: the return on expenditure achieved for lipid therapy (REALITY) study.

Paragh G, Márk L, Zámolyi K, Pados G, Ofner P.

Clin Drug Investig. 2007;27(9):647-60.PMID: 17705573 [PubMed - indexed for MEDLINE]Related articles

Forecasting cholesterol management--end of the statin gold rush?

Crownover BK, Curtiss FR.

J Manag Care Pharm. 2006 Jul-Aug;12(6):479-85. Review. No abstract available. PMID: 16925456 [PubMed - indexed for MEDLINE]Related articlesFree article

Strategies for the management of hypercholesterolaemia: a systematic review of the cost-effectiveness literature.

Morris S, McGuire A, Caro J, Pettitt D.

J Health Serv Res Policy. 1997 Oct;2(4):231-50. Review.PMID: 10182252 [PubMed - indexed for MEDLINE]Related articles

[Coronary heart disease patient reaches LDL level of 100 mg/dl with atorvastatin: how do you continue treatment next year?]

Weizel A, Sawicki PT.

MMW Fortschr Med. 2004 Dec 16;146(51-52):14, 16. German. No abstract available. PMID: 15675236 [PubMed - indexed for MEDLINE]Related articles